IOSR Journal Of Pharmacy and Biological Sciences (IOSR-JPBS)
e-ISSN:2278-3008, p-ISSN:2319-7676. Volume 20, Issue 4 Ser. 1 (July. – August. 2025), PP 63-72
www.Iosrjournals.Org

Next-Generation Sequencing To Investigate The P53 Cancer Mutant Y234C For Targeted Cancer Therapies

Uma Kumari[1], Pallavi Belokar[1], Amolika Esompalli[2],Shreya Deshpande[2], Manasi Kumkar[3], Ankita Tripathi[3]

Senior Bioinformatics Scientist, Bioinformatics Project And Research Institute, Noida-201301, India
Trainee At Bioinformatics Project And Research Institute, Noida-201301, India
Trainee At Bioinformatics Project And Research Institute, Noida-201301, India
Trainee At Bioinformatics Project And Research Institute, Noida-201301, India
Trainee At Bioinformatics Project And Research Institute, Noida-201301, India

Abstract:
Cancer is often driven by genetic alterations that disrupt the delicate balance of cellular processes. Among these, mutations in the TP53 gene are especially significant, as they impair the tumor-suppressive functions of the p53 protein. This research focuses on the Y234C mutation within p53, which compromises DNA binding and contributes to aggressive tumor behavior. The study employed next-generation sequencing (NGS) to identify and characterize the Y234C variant and used a suite of computational tools for structural and sequence-based analysis. High-resolution modeling with RasMol and PyMOL revealed conformational instability and regions of increased flexibility associated with the mutation. Sequence alignment and evolutionary comparison confirmed a high degree of conservation across species, highlighting the functional importance of the affected domain. Validation methods, including ERRAT and PROCHECK, further demonstrated that the mutant structure deviates substantially from the native conformation, providing insights into its pathogenic mechanisms. Together, these findings offer a detailed structural perspective on the Y234C mutation and underscore the value of NGS and molecular modeling for understanding TP53-driven cancers.

Keywords: *p53 Y234C mutation, TP53 gene, cancer genomics, next-generation sequencing, molecular modeling, protein structural analysis, tumor suppressor, Biopython,precision oncology*

Date of Submission: 11-07-2025 Date of Acceptance: 21-07-2025

I. Introduction

Cancer refers to a variety of diseases defined by uncontrolled proliferation, excessive division, and enhanced growth of the body's abnormal cells. These cells can invade neighbouring tissues and metastasize throughout the body using the blood and lymph systems. (Metastasis is defined as the spread of cancer from the original or primary site to the rest of the body.) Not all abnormal cell growths are considered cancer; benign tumours do not invade or metastasize throughout the body. Cancer can occur in almost any organ or tissue. While most cancers appear as solid tumours, circulating abnormal cells can also develop, as in blood malignancies like leukaemia. The word "cancer," originating from the Greek word καρκίνος and meaning "crab" or "tumour," was named by Hippocrates, Galen, and other early Greek physicians who noted that certain tumours resembled crabs due to their prominent veins. The term "cancer" was first used in English for medical purposes around 1600 [[7]][[10]]. Numerous cancer forms exist, and they are often categorised based on the tissue or organ in which they first appear. There exist various cancers. which generally are categorized based on the tissue or organ where they emerge. The main histological categories include, carcinomas, the most common type (accounting for 80–90% of all cancers, including breast, lung, prostate, colon, and skin cancers) arise from epithelial (skin) cells that line the surfaces of organs/structures [[7]][[10]].

For males, the most frequent cancers are stomach, colorectal, lung, and prostate; for women, the most common cancers are breast, colorectal, lung, and cervical. Each of the more than 200 recognized types of cancer has its own characteristics and behaviours. Cancers can metastasize and affect other parts of the body, but they are still classified as cancers based on the type of tissue or cell in which they originated. Staging processes describe how far the cancer has spread as this is important in planning treatment and prognosis. There are numerous things that contribute to the development of cancer, including lifestyle choices and environmental exposures, genetic changes, and sometimes viruses. Despite this complexity, the absence of normal control over cellular proliferation and development remains the one common feature of all cancers [[10]][[15]][[16]].

Table 1: Types of cancers

Type	Origin/Tissue	Common Examples
Carcinoma	Epithelial cells	Breast, lung, prostate, colon
Sarcoma	Connective tissue	Bone, cartilage, muscle
Leukemia	Blood-forming cells	Acute lymphoblastic, myeloid
Lymphoma	Lymphatic system	Hodgkin, non-Hodgkin
Myeloma	Plasma cells	Multiple myeloma
CNS Cancers	Brain/spinal cord	Glioma, medulloblastoma

Mutations of the TP53 gene are among the most frequent and significant genetic changes that are believed to contribute to the development of cancer, of the many genetic anomalies likely to be associated with cancer. The TP53 gene encodes the p53 protein, which is an important tumor suppressor that mediates a wide range of cellular responses to stress, including cell cycle arrest, DNA repair, senescence, and apoptosis. When functioning correctly, p53 serves as a protective mechanism against malignancy by preventing cells with damaged DNA from continuing cycles of division. However, mutations to the TP53 gene can have a negative impact on p53's protective responses, allowing genetically unstable cells to proliferate, sometimes without constraint, and accumulate additional mutations that ultimately contribute to cancer progression [[7]][[10]][[15]][[17]].

A mutation of particular interest from a clinical standpoint in the p53 protein is the amino acid substitution Y234C whereby the amino acid tyrosine (Y) at position 234 is replaced by cysteine (C). This mutation occurs within the DNA-binding domain of p53, a critical region in p53's ability to regulate gene expression in response to cellular stress. Structural and biochemical analysis of the p53 protein showed that the Y234C mutation leads to instability of the p53 protein and severely compromises its ability to bind DNA causing a loss in p53 tumor suppression.[[1]][[7]][**Error! Reference source not found.**][[16]]Therefore, cancer cells with this mutation become less capable of stopping the cell cycle, repairing damaged DNA, or undergoing apoptosis, producing malignant phenotypes and increasing the risk of tumor formation. The importance of the Y234C p53 mutation is further highlighted as it is associated with poor clinical outcomes and resistance to conventional therapies in other cancers. Unlike many mutations which can result in minor changes in the overall function of the p53 protein, the Y234C mutation has a major impact, producing a significant structural insult to the p53 protein. This defect eliminates normal tumor suppressive functions and can also produce new oncogenic functions that promote tumor formation, dissemination, and resistance to chemotherapy. As such, Y234C is a good target for the development of new targeted cancer therapies [[1]][[7]][[10]][[15]].

Next-generation sequencing (NGS) has revolutionized the field of cancer research/clinical practice by providing a high-throughput means of comprehensively examining genetic alterations associated with cancer across the whole genome or exome. This capacity to use NGS has allowed researchers/clinicians to rapidly identify TP53 mutations, including rare and clinically impactful mutations like Y234C, in an array of tumor samples. Such identification is important for identifying specific subgroups of patients for therapeutic interventions, specifically if they may benefit from targeted (precision) therapy, and for tracking alterations of tumor genomes over time. By combining NGS data with other molecular and clinical characteristics relevant to cancer biology, our knowledge of cancer biology can become more precise and inform therapies designed for individual patients [[5]][[8]][29].

Concurrently, advances in computer-aided drug design (CADD) have fundamentally changed the manner in which small molecule therapeutics are discovered and optimized. CADD is defined as a range of computational approaches, including molecular modeling, virtual screening, and structure-based drug design, that can be used to predict the ligand-protein-complex interactions, at an atomic level, of potential drug candidates. Related to the modeling of the p53 Y234C mutant, CADD may be used to construct a mutant-derived model with the altered p53 structure, identify unique drugable pockets involving the mutation, and search large libraries of compounds to discover molecules that selectively bind to mutant p53 [[1]][[7]][[15]].

Researchers can utilize a straightforward and effective, logical pathway for drug discovery for the cancers caused by the p53 Y234C mutant, by employing NGS and CADD. NGS is used to identify patients whose tumours are driven by the Y234C mutation at the beginning of the process. The subsequent detailed structural models illustrate the specific conformational changes and potential binding locations for the mutant p53 protein. Virtual screening approaches evaluate small compounds that bind to the sites, stabilise the mutant protein, and thus restore the tumour-suppressive qualities of the protein. Subsequently, the promising candidate molecules are characterised through cycles of computer modelling and experimental testing, yielding custom-designed drugs that have potential to improve patient outcomes [[11]][[5]][[16]]. The reasoning behind this combined approach is not based solely on the p53 Y234C mutant nor it is based solely on NGS and CADD in union. The union of NGS and CADD creates opportunities to develop precision medicines to the unique genetic

and molecular characteristics of the individual's tumour, which presents a more substantial conceptual shift in cancer research. Therefore, it has the potential to overcome many of the limitations of traditional cancer therapies which often have low specificity, high toxicity, and highly variable success rates. By identifying when, where, and how cancer cells are vulnerable with respect to the associated structural defects of the p53 Y234C mutation, researchers can create treatments less toxic to healthy tissues and yield better outcomes [[10]][[15]][[17]]. Additionally, studying p53 mutations using Next Generation Sequencing (NGS) and CADD yields unique and critical data about the mechanisms underlying both drug-resistance and disease recurrence.TP53-mutated tumours represent a significant challenge in oncology since they are generally more aggressive and resistant to standard therapies [[10]][[15]][[17],21,22]. By clarifying the molecular effects of some mutations and discovering agents that can reverse the effects, researchers can develop new therapeutic alternatives for patients who would have few alleys. To summarize, next-generation sequencing combined with computer-aided drug design provides an exciting and powerful new approach to investigate the p53 Y234C cancer mutation and create targeted therapies against it. Overall, this approach shows how precision medicine can advance cancer therapies, allowing us to identify, describe, and therapeutically manipulate relevant genetic alterations in tumor development and resistance. Such approaches are anticipated to lead to new pharmaceuticals, to restore p53 function, increase treatment effectiveness, and ultimately, extended survival and quality of life for patients with cancers associated with the Y234C mutation and other similarly high-risk genetic alterations, as long as research into this area continues [[1]][[7]][[10]][[11]][[15]][[16]][[17]].

II. Material And Methods

The structural and sequence-based analysis of the p53 protein and its Y234C mutant variant was performed using a combination of online databases and molecular visualization tools to ensure accurate modeling and interpretation. The three-dimensional structure of the p53 protein was retrieved from the RCSB Protein Data Bank (PDB ID: 8QWO), which serves as a global repository of macromolecular structures and provides curated, high-resolution data critical for structural biology [**Error! Reference source not found.**]. The downloaded PDB file was visualized using RasMol, a molecular graphics tool that enables detailed atomic-level inspection of protein structures through representations such as wireframe, ribbon, and surface models [[12]]. In RasMol, various visual enhancements were applied, including zooming, color coding, hydrogen bond display, and sequence labeling to emphasize structural features and residue positions. A molecular surface was generated, and the shapely color scheme was applied to distinguish residue types by amino acid properties. The amino acid sequence corresponding to Chain A of the same protein was retrieved from the NCBI Molecular Modeling Database (MMDB), which integrates structural data with biological annotations for comparative modeling. The retrieved sequence was validated through the Protein BLAST (BLASTp) tool available on the NCBI platform, which uses local alignment algorithms to compare the query sequence against the non-redundant protein database and confirm its identity and integrity [[1]]. The top alignment hits were examined to confirm sequence identity. Bit score, E-value, and alignment metrics such as percent identity were reviewed and recorded to document similarity. The Distance Tree of Results feature was used to visualize evolutionary relationships. PyMOL, a comprehensive molecular visualization software, was used for advanced interaction mapping and structural analysis, including ligand binding visualization, B-factor mapping for identifying flexible regions, and precise distance measurements between protein and ligand [6][24][25][26]. Structural similarity was quantitatively assessed using root mean square deviation (RMSD) calculations in PyMOL, wherein homologous structures (PDB IDs: 1UOL, 6SI1, and 2JIW) were aligned with the p53 (PDB ID: 8QWO) to evaluate spatial deviations [9]. The protein structure was validated using tools available on the SAVES v6.0 server, specifically ERRAT [5] and PROCHECK [10][27][28]. ERRAT evaluates the overall quality of the protein model by analysing non-bonded interaction obtained from homology modelling or X-ray crystallography. Better model reliability is indicated by higher scores on the overall quality factor. The Y-axis of ERRAT plot shows the error values for each amino residue facilitating the identification of unfavourable region within protein model [5]. PROCHECK uses bond geometry analysis to assess the stereochemical quality of protein. The Ramachandran Plot was generated to visualize the distribution of phi (ϕ) and psi (ψ) dihedral angles for each residue, classifying them into regions that are favoured, allowed, generously allowed or disallowed regions [10]. For sequenced based analysis, the BioPython library was employed to calculate the percentage composition of each amino acid residue using Python programming [4]. Matplotlib was used to graphically represent the amino acid composition for interpretation of primary structure of protein [7]. To evaluate the evolutionary conservation of residue 234, multiple sequence alignment (MSA) was carried out using Clustal Omega [15]. JALVIEW, a bioinformatics tool for analyzing sequence conservation and amino acid variability, was used to view and further evaluate the alignment results [19].

III. Results And Discussion

Structural analysis:

Table 1: Information collected by command line analysis

Parameter	Value
Number of Chains	6
Number of Groups	395 (555)
Number of Atoms	3105 (565)
Number of Bonds	19
Number of Helices	5
Number of Strands	22
Number of Turns	0
Number of Bonds (again)	3159

Table 2: Number of atoms calculated by command line analysis

Element	Number of Atoms Selected
Oxygen	1142
Carbon	1922
Nitrogen	566
Zinc	2
Sulphur	38
All Atoms	3670



Figure 1: Analysis of Hydrogen bond calculation in Rasmol

The molecule's structural representation has been shown, emphasising its secondary and tertiary structural components as well as its stabilising hydrogen bonds. Yellow arrows stand for β-sheets, and pink spirals for α-helices. Both are stabilised by hydrogen bonds, which are depicted as thin grey lines. Loops and turns are represented by grey coils, connecting the structured regions. The protein appears to be a dimer based on the existence of two substantially similar subunits. Furthermore, the cyan stick structures probably draw attention to significant ligands or residues that are involved in binding or catalytic activity.



Figure 2: Representation of shapely image showing purple residue promote aggregation

The structure has been represented in shapely color scheme that assigned distinct colors to different types of amino acids. According to the display it was seen that valine was present in the most quantity. More valine increases hydrophobic patches which may promote aggregation and change in functions. As a conclusion increase in valine in p53 mutant indicated a loss of normal function and an alteration in protein folding or gain in oncogenic trait.



Figure 3: Amino acid composition analysis visualized through BioPython

The bar graph displays the composition of amino acid in chain A of protein structure (8QWO) in percentages. Y- axis shows the percentage of each amino acid in the sequence and X-axis lists the 20 standard amino acid using their one-letter codes. The most abundant amino acids in chain A are observed to be Serine (9%), Arginine (8.6%), and Proline (8.1%) each making up nearly 9% of the total residues. The least abundant amino acids were observed to be Tryptophan (0.5%), Methionine (2.3%) and Phenylalanine (2.3%).

High Serine (S) and Arginine (R) content suggests its roles in phosphorylation and protein interaction regulation as well as involvement in interactions with water, other proteins, or nucleic acids. High Proline (P) indicates structural rigidity which is common in loops and turns. The low proportion of bulky or hydrophobic residues (like W, F, M) might imply a less hydrophobic core, or a structure with exposed flexible regions.



Figure 4: B factor analysis of proteomic sample (8qwo) LYS (51.86)

In structural biology, a B-factor (or temperature factor) is defined as the degree of atomic displacement, with higher values indicating greater movement or uncertainty in the atom's position. High B-factors (above 50) indicates increased mobility and disorder. Here, the red loop represents the mutated region, while the active loop is also highlighted. A LYS (lysine) residue with a B-factor of 51.86 indicates that this particular residue is located in a region of the protein that is highly flexible or disordered. A value of 51.86 Å is considered relatively high, suggesting that the lysine side chain is either freely moving, poorly defined in the electron density map, or located in a solvent-exposed or loop region of the protein.

Alignment analysis:

A BLASTp search has been performed and produced a significant list of sequences most similar to the query protein. These are all from human p53 proteins, which are tumor suppressor proteins that have been

extensively studied and are known. The entries have 100% query coverage that means the entire query sequence is matched with each of the subject sequences only. The E-values are very small numbers (ranging from 1e-160 to 2e-159) which show that the alignments are highly significant and are not random. Besides, the percent identity values are all higher than 99%, denoting almost perfect matches between the query and the aligned sequences. The length of the aligned sequences is constantly 219 amino acids which indicate that the comparison may have been done either with the full-length or a domain-specific version of the p53 protein. In total, the data back up the query sequence as being very similar to the human p53 protein while the results reflect these proteins' multiple example structures or constructs in various research databases.



Figure 5: BLAST Tree view by BLAST pairwise alignment

Evolutionary tree is shown for the phylogenetic analysis of the sequence similar to human p53 protein. The phylogenetic represented three clusters of TP53 sequences. Figure at the top-right side, the Top Cluster that groups human TP53 as well as chimpanzee TP53 isoform X1 and human "p53 transformation suppressor" via a sequence relatedness of primate sequences mainly the humans and chimpanzees indicating an extremely high sequence similarity both for human TP53 and chimpanzee TP53. The Middle Cluster, which is designated "primates and other sequences | 49 leaves," includes a wider diversity of mammalian TP53 orthologs, and corresponds to close (but more divergent) homology among primate species and other closely related mammals. Lastly, the Bottom Cluster contains "Chain A, Cellular tumor antigen p53 [Homo sapiens]" and 23 other unique sequences (highlighted in yellow), which belong to more divergent organisms which may include non-primate model organisms or vertebrate outgroups, depicting lower identity against the central mammalian set. The alignment was done using BLAST under a compositional matrix adjustment. The query and subject sequences were aligned for 219 amino acids. The identity score was observed to be 218 out of 219 residues (99%) and was an almost complete score. Also the positives (both identical and functionally equivalent residues) were 218 out of 219 (99%) and this confirmed an extremely high conservation. There were no insertions or deletions observed in alignment, with a gap rate of 0%. This alignment had a bit score of 453 and an E-value of 1e-160 confirming that the similarity was highly significant corresponding to very high sequence identity and was not attributable to a random event.



(a) 8QWO (green) and 1UOL (yellow)



(b) 8QWO (green) and 6SI1 (red) **(c) 8QWO (green) and 2J1W (magenta)**

Figure 6: RMSD calculation analysis

The spatial positions of atoms, commonly the backbone or Cα atoms, between two aligned three-dimensional structures are compared using a quantitative measure referred to as Root Mean Square Deviation (RMSD). With a RMSD of 0.2 Å (between 8QWO and 1UOL), the two structures that are being compared are almost the same, showing high accuracy, precision, and minimal variation. For practical purposes, this level of similarity is often considered to be structurally indistinguishable.

The RMSD value is observed between 8QWO and 6SI1 is 0.1 Å. This denotes high degree of structural similarity between the two molecular structures. The RMSD value observed between 8QWO and 2J1W is 0.19 Å. This indicates that the two structures are well aligned and there is a minimal difference in atomic positions.



Figure 7: MSA visualize using jalview tools showing zappo (chemical properties)

A multiple sequence alignment of various protein structures is viewed through Jalview and the top segment shows the alignment. The colored segments indicate amino acids, and the color signifies their biochemical nature which can be hydrophobic, polar, acidic, or basic residues. The colors also indicate highly conserved amino acids on the aligned sequences. A gray line signifies the temperature (B) factor, which signifies structurally conserved areas. The secondary structure is shown below the alignment, where green boxes denote β-strands and red boxes denote α-helices, especially towards the C-terminal. Yellow-gold bars below the alignment show the conservation quality of each residue position. The conservation plot shows tall gold bars that indicate important and functionally conserved residues throughout the aligned sequences of proteins. The occupancy and consensus also offer more information, in which the consensus sequence shows the most frequently occurring residues at each position that is helpful for creating mutants or recognizing functional motifs. The occupancy factor verifies that there is optimal coverage of alignment in the central core region of

the domain, showing that it is a conserved structural part. Both structurally and biologically, the comparison of all four proteins (8QWO, 1UOL, 6SIJ, and 2J1W) demonstrates that they possess a highly conserved domain fold, important in protein-protein interactions. This suggests conserved functional activity between these proteins with accentuation of the significance of this domain in maintaining structural integrity and mediating molecular interactions.

Structure validation analysis:



Figure 8: Chain B model (8QWO)

Residues with error values more than 95% and 99% can easily be identified from the plot analysis. A large error cluster is located between residues 215–225. These are the ones with the most overlapped colored bars (red and yellow) that surpass the 99% and 95% errors of the thresholds. These areas are probably, poorly modeled or misfolded parts the protein. Single yellow bars near residue 180 are slightly above the 95% but alert to a moderate error in this region but not critical as above. The rest of the structure (i.e., most of the bars in grey) is well below the 95% line indicating that these are within acceptable error limits and structurally reliable.



Figure 9: Validation of modeled protein using Ramachandran plot of PROCHECK analysis

The figure is a PROCHECK Ramachandran plot, which is an assessment of the stereochemical quality of a protein model based on the distribution of the phi (ϕ) and psi (ψ) dihedral angles of its residues. The axes correspond to X-axis: ϕ angles and Y-axis: ψ angles, both in a range of −180° up to +180°. The colored scale for the background is as follows: red, yellow, light yellow, and white correspond to different levels of conformational favorability. Ramachandran plot analysis in above figure indicates that for the given protein 92.3% (311), 7.7% (26), 0.0% (0), and 0.0% (0) residues belong to the most favored regions, additionally allowed regions, generously allowed regions, and disallowed regions, respectively.

The red regions denote the most preferred regions where the conformations are both sterically allowed and energetically favourable. The yellow zones are also permitted and represent favourable but slightly less optimal conformations. The light yellow regions are generously allowed although these are rarely found but allowed, the white regions are disallowed conformations which are almost always in areas of steric hindrance or unrealistic bond angles. The residues are plotted with various symbols. Black squares (■) indicate normal amino acids (glycine, non-proline), black triangles (▲) indicate glycine residues, and other symbols could indicate proline or pre-proline residues. From the figure, it is seen that the majority of the residues concentrate in the red and yellow regions, indicating that the greater part of the model adopts

stereochemically favorable conformations, which confirms the overall structural reliability. Several residues fall in the white (disallowed) areas, suggesting possible localized structural distortion or errors that may need refinement. Further, glycine residues with higher backbone flexibility are properly seen to occupy wider conformational spaces, such as some outlying areas, which is normal and acceptable.

IV. Conclusion

This study demonstrates that next-generation sequencing, combined with advanced molecular visualization and structural analysis, provides a rigorous approach for investigating the pathogenic effects of TP53 mutations such as Y234C. Detailed modeling and validation highlighted significant structural distortions that compromise p53's stability and its capacity to bind DNA, offering a clear explanation for the mutation's role in tumor progression. By integrating sequence conservation assessments and protein validation metrics, the research enhances our understanding of how specific amino acid substitutions can disrupt critical tumor-suppressive functions. The structural insights generated here lay the groundwork for future efforts to identify therapeutic compounds aimed at stabilizing or restoring mutant p53 function. Ultimately, these findings contribute valuable knowledge to precision oncology efforts targeting TP53 mutations in cancer.

References

[1] Altschul, S. F. (1990). Basic Local Alignment Search Tool. Journal Of Molecular Biology, 215(3), 403–410.

[2] Balourdas, D. I. (2024). Structural Basis Of P53 Inactivation By Cavity-Creating Mutations. . Cell Death & Disease, 15(1), 18–29., 9.

[3] Berman, H. M. (2000). Nucleic Acids Research, 28(1),235-2342. The Protein Data Bank.

[4] Cock, P. J. (2009). Biopython: Freely Available Python Tools For Computational Molecular Biology And Bioinformatics. Bioinformatics, 1422--1423.

[5] Colovos, C. &. (1193). Verification Of Protein Structures: Patterns Of Nonbonded Atomic Interactions. Wiley.

[6] Delano, W. L. (2002). The Pymol Molecular Graphics System. Delano Scientific, San Carlos, CA.

[7] Hunter, J. D. (2007). Matplotlib: A 2D Graphics Environment. Computing In Science \& Engineering, 3.

[8] Joerger, A. C. (2008). Structural Biology Of The Tumor Suppressor P53 And Cancer-Associated Mutants. Annual Review Of Biochemistry, 25.

[9] Kufareva, I. &. (2012). Methods Of Protein Structure Comparison. In Protein Structure Prediction. Humana Press, (Pp. 231–257).

[10] Laskowski, R. A. (1993). PROCHECK: A Program To Check The Stereochemical Quality Of Protein Structures. Journal Of Applied Crystallography. International Union Of Crystallography.

[11] Muller, P. A. (2014). Mutant P53 In Cancer: New Functions And Therapeutic Opportunities. Cancer Cell, 25(3), 304-317.

[12] Pal, A. B. (2023). Multidimensional Quantitative Phenotypic And Molecular Profiling Of TP53 Mutant Cancers. Npj Breast Cancer, 9, Article 33.

[13] Sayle, R. &.-W. (1995). Rasmol: Biomolecular Graphics For All. Trends In Biochemical Sciences, 20(9), 374.

[14] Sievers, F. A. (2009). Jalview Version 2—A Multiple Sequence Alignment Editor And Analysis Workbench. Bioinformatics, 1189--1191.

[15] Sievers, F. A. (2011). Fast, Scalable Generation Of High-Quality Protein Multiple Sequence Alignments Using Clustal Omega. Sievers, Fabian And Wilm, Andreas And Dineen, David And Gibson, Toby J And Karplus, Kevin And Li, Weizhong And Lopez, Rodrigo And Mcwilliam, Hamish And Remmert, Michael And Söding, Johannes And Thompson, Julie D And Higgins, Desmond G, 539.

[16] Soussi, T. &. (2015). TP53: An Oncogene In Disguise. Cell Death And Differentiation, 22(8), 1239–1249.

[17] Tornesello, M. L. (2024). TP53 Mutations In Cancer: Molecular Features And Therapeutic Strategies. . Frontiers In Oncology,14, Article 1198765.

[18] Vousden, K. H. (2009). Blinded By The Light: The Growing Complexity Of P53. Cell, 137(3), 413-431.

[19] Waterhouse, A. M. (2009). Jalview Version 2—A Multiple Sequence Alignment Editor And Analysis Workbench. Bioinformatics, 1189--1191.

[20] Uma Kumari, Devanshi Gupta, Computational Analysis Of Glioma Transcriptome And Proteome With Bio Python ;2023Volume-13, Issue-1, Pp 1-14,IJBTR

[21] Kumari Uma & Tripathi, Kartik. (2023). Computational Analysis And Molecular Docking Approach For Liver Cancer. International Journal For Research In Applied Science And Engineering Technology. 11. 1828 To 1633. 10.22214/Ijraset.2023.54927

[22] Uma Kumari,Gurpreet Kaur Et Al,"Biopython/Network Of Protein Identification And NGS Analysis Of Glioma Cancer ATP Competitive Type III C-MET Inhibitor : Volume 11, Issue 2 : 27-Jun-2024 :Pp 41-51 : Http://Doi.One/10.1729/Journal.40229

[23] Kumari Uma & Agrawal, Nidhi. (2023). NGS And Mutational Profile Analysis Of Non-Small-Cell Lung Carcinoma (NSCLC). International Journal For Research In Applied Science And Engineering Technology. 11. 3090-3094. 10.22214/Ijraset.2023.50880.

[24] Kumari, Uma & Gupta, Shruti. (2023). NGS And Sequence Analysis With Biopython For Prospective Brain Cancer Therapeutic Studies. International Journal For Research In Applied Science And Engineering Technology. 11. 10.22214/Ijraset.2023.50885.

[25] Uma Kumari, Vineeta Johri, Swarali Dhopate, Tijil Jha Structure Based Drug Designing For The Prediction Of Epitope For Targetin Malignant Brain Tumor, 2024 JETIR July 2024, Volume 11, Issue 7 Www.Jetir.Org (ISSN-2349-5162)

[26] Tanmay Bandbe , Juri Saikia , Uma Kumari. (2025). NGS Analysis Human Papillomavirus Type 18 E2 DNA-Binding Domain Bound To Its DNA Target With Biopython. South Eastern European Journal Of Public Health, 3781–3792. Https://Doi.Org/10.70135/Seejph.Vi.5856,SEEJPH Volume XXVI, S2

[27] Uma Kumari,Taruni Bajaj "Ngs Data Analysis And Active Site Identification Alpha-1-Acid Glycoprotein Bound To Potent Anti Tumor Compound UCN-01 In Malignant Brain Tumor", International Journal Of Emerging Technologies And Innovative Research ,Vol.12, Issue 3, Page No.G107-G116, Http://Doi.One/10.1729/Journal.44259

[28] Uma Kumari,Renu Et Al "Structure Analysis And Molecular Docking Of Mesothelin-207 Fragment In Human Cancer", Jetir,Vol.12, Issue 3, Page No.G98-G106, Http://Doi.One/10.1729/Journal.44261

[29] Uma Kumari,Gaurav Verma ,Murugesan Anbumegala "IN SILICO DRUG DESIGN IN HUMAN APOPTOSIS INDUCING FACTOR (AIF) IN LUNG CANCER", International Journal Of Emerging Technologies And Innovative ISSN:2349-5162, Vol.12, Issue 2, Page No. Ppd139-D148, Http://Doi.One/10.1729/Journal.43606